The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2022 | Highlights at COSTEM 2022
Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides his highlights from the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), including discussions comparing CAR-T therapy with bispecific T-cell engagers (BiTEs) in multiple myeloma, as well as CAR-Ts with transplantation in myeloma and lymphoma. Dr Giralt additionally mentions debates relating to measuring MRD positivity before or after transplantation. This interview took place at COSTEM 2022 in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
